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ABSTRACT
Glioblastoma multiforme (GBM) is the most common primary brain tumour 
in adults and one of the most aggressive cancers. PARP-1 is a nuclear protein 
involved in multiple facets of DNA repair and transcriptional regulation. In this study 
we dissected the action of PARP inhibition in different GBM cell lines with either 
functional or mutated PTEN that confers resistance to diverse therapies. In PTEN 
mutant cells, PARP inhibition induced a severe genomic instability, exacerbated 
homologous recombination repair (HR) deficiency and down-regulated the Spindle 
Assembly Checkpoint (SAC) factor BUBR1, leading to mitotic catastrophe (MC). 
EGFR gene amplification also represents a signature of genetic abnormality in GBM. 
To more effectively target GBM cells, co-treatment with a PARP inhibitor and an 
EGFR blocker, erlotinib, resulted in a strong suppression of ERK1/2 activation and 
in vivo the combined effect elicited a robust reduction in tumour development. In 
conclusion, PARP inhibition targets PTEN-deficient GBM cells through accentuation of 
SAC repression and aggravation of HR deficiency, leading to the induction of genomic 
instability and eventually deriving to mitotic catastrophe (MC); the inhibition of PARP 
and co-treatment with an inhibitor of pro-survival pathways strongly retarded in vivo 
gliomagenesis. 
INTRODUCTION
Glioblastoma multiforme (GBM) are lethal brain 
tumours, highly resistant to therapy. An important 
improvement in therapeutic response came from the use of 
the alkylating agent temozolomide (TMZ) in combination 
with ionizing radiation (IR). Amongst the huge number 
of genetic alterations that populate the GBM genomic 
landscape, five genetic changes dominate: loss of tumour 
suppressor and aging biomarker (Ink4a), acute renal 
failure (Arf), cellular tumour antigen p53, or phosphatase 
and tensin homolog on chromosome 10 (PTEN); and 
amplification of Epidermal Growth Factor Receptor 
(EGFR). 
Loss of PTEN is a very prominent event during 
gliomagenesis, occurring in about 36% of GBMs [1-3]. 
PTEN is a lipid phosphatase with a canonical role in 
turning-off the phosphatidylinositol 3-kinase (PI3K)-Akt-1 
signalling pathway; hence, loss of PTEN has oncogenic 
consequences during gliomagenesis [4]. In addition, it is 
becoming increasingly clear that PTEN has novel nuclear 
functions, including transcriptional regulation of the 
RAD51 gene, whose product is essential for homologous 
recombination (HR) repair of DNA breaks [5].
The nuclear protein PARP-1, known to function as 
a DNA damage sensor and to play a role in various DNA 
repair pathways, has recently been implicated in a broad 
variety of cellular functions, including transcriptional 
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regulation [6, 7]. PARP inhibitors exhibit antitumour 
activity in part due to their ability to induce synthetic 
lethality in cells deficient for homologous recombination 
repair [8-12] and also in triple negative breast cancer 
cells [13, 14]. Up to date, the studies on GBM and PARP 
inhibitors have focused on the use of these small molecules 
as radio or chemo-potentiators [15-17]. In this study, we 
report that primary glioma stem-like cells are targeted in 
their ability to form neurospheres by PARP inhibitors; 
moreover, mutant PTEN GBM cells are also sensitive to 
PARP inhibitors by increasing genomic instability leading 
to impaired G2/M arrest and MC. Additionally, PARP 
inhibition strongly intensified HR deficiency in PTEN 
mutant cells, that had already compromised HR [18-20] 
and repressed the Spindle Assembly Checkpoint protein 
BUBR1. Moreover, the combination of PARP inhibition 
with an upstream blocker of pro-survival signalling 
pathways arising from the EGFR, the EGFR inhibitor 
erlotinib, induced a dramatic reduction in tumour growth 
in an orthotopic mouse model. Thus, taking advantage of 
PARP inhibitor-induced cell death in PTEN-mutant glioma 
cells prone to genomic instability, and disabling survival 
pathways through EGFR and PARP inhibition, could be 
therapeutically exploited in the treatment of this malignant 
tumour. 
RESULTS 
PJ34 and olaparib interfere with neurospheres 
formation in primary glioma cells and impacts 
differently on cell viability in PTEN wild type and 
PTEN-mutant glioma cells
As a first approach to analyze the potential of PARP 
inhibition (PARPi) as monotherapy against GBM we 
evaluated self-renewal capability, which is a marker of 
stemness in GSCs, using neurospheres formation assay 
in primary patient-derived PTEN-proficient GSCs TG1 
[21] with two different PARP inhibitors: PJ34 (IC 20 
nM) and olaparib (IC 5 nM). PJ34 targets mainly PARPs 
synthesizing proteins but some off-target effects have also 
been reported, suggesting the effect of PJ34 on cancer cells 
may not be attributed exclusively to PARP inhibition [22, 
23]. For that reason we also used the clinically relevant 
PARPi olaparib. Following seven days of treatment, 
neurospheres formation decreased significantly with 
either PJ34 or olaparib (figure 1A). Similar results have 
been reported by Rich and colleagues showing that PARPi 
preferentially targeted GSCs [16]. Our data support that 
PARPi targets primary glioma cells in part by perturbing 
self renewal/GICs phenotype. 
PTEN deficiency is one of the most common 
mutations in human high grade gliomas, and renders these 
tumours resistant to radio and chemotherapy, conferring 
increased invasive properties. To further challenge PARPi 
as anti GBM agents we tested them against established 
GBM cell lines bearing either wild type or mutant PTEN. 
Treatment with PARPi of either PTEN wild type or 
mutant cell lines resulted in loss of cell viability (figure 
1B, figure S1A) and cell death induction (figure 1C). Due 
to the previously reported off-target effects of PJ34, the 
PARP inhibitor olaparib was also tested, exerting similar 
results (figure S4A). Interestingly, PTEN deficient cells 
including U87MG displayed an increased sensitivity to 
PARPi. However, U87MG, which has been previously 
described to be extremely resistant to apoptotic cell 
death [24], hardly increased apoptosis following PARPi 
(figure 1D, S1B,C) or PARP-1 knockdown (figure S1D) 
when compared with LN229 (PTEN proficient cell 
line). Remarkably, PTEN silencing in LN229 cells and 
PTEN restoration in U87MG cells resulted in increased 
apoptotic cell death following PARPi (figure S2A,B). This 
apparently contradictory result may be explained through 
the genetic context of each cell line: while LN229 cells 
possess a functional apoptotic machinery that is activated 
following PARP inhibition, PTEN re-introduction in 
U87MG cells partially restored apoptotic ability. 
Combining PARPi with the methylating agent 
temozolomide (TMZ) or ionising radiation (IR) did 
not potentiate cell killing (figure S3A,B,C and data not 
shown). Thus, PARP inhibition per se was sufficient to 
induce cell death in PTEN deficient cells more efficiently 
than the currently used chemotherapeutic drug TMZ or IR. 
Moreover, the G2/M arrest was also notably diminished in 
U87MG cells following PARP inhibition respect to PTEN 
wild type cells (figures 1E,1F and S4B) and U87MG cells 
transiently restored with PTEN partially recovered G2/M 
arrest (figure S2C). In addition, TMZ remarkably induced 
an arrest in G2/M at 72 hours and the combination with 
PARPi produced similar effect to PARP inhibition alone 
(figure S3D).
PARP inhibition induced down-regulation of the 
spindle assembly checkpoint protein BUBR1 
leading to mitotic instability in PTEN deficient 
glioma cells
To further elucidate the mechanistic aspects 
regarding the effect of PARP inhibition in both PTEN 
proficient and PTEN mutant GBM cells we explored the 
induction of genomic instability. PTEN deficient cells 
lack G2/M arrest following PARPi treatment (figure 1E 
and F). The BUBR1 protein ensures accurate segregation 
of chromosomes through its role in the mitotic checkpoint 
and the establishment of proper microtubule-kinetochore 
attachments; and sustained high-level expression of 
BUBR1 preserves genomic integrity [25]. In figure 2A 
we show that PARP inhibition induced BUBR1 down-
regulation in U87MG PTEN-deficient cells, suggesting 
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that the Spindle Assembly Checkpoint is compromised 
in U87MG. Further confirmation for the effect of PARP 
inhibition on BUBR1 levels was established by the use of 
a different PARP inhibitor, olaparib, that induced BUBR1 
down-regulation in U87MG but not in LN229 cells (figure 
S4C). Furthermore, silencing PTEN in LN229 cells also 
results in BUBR1 decrease after PARP inhibition (figure 
2B) while introduction of PTEN in U87MG cells delayed 
BUBR1 loss (figure 2B). In addition, in silico analysis 
using the database Array Express of U87MG cells 
transduced with wild type PTEN showed a statistically 
significant decrease in BUB1B expression (the gene 
for BUBR1) in PTEN transduced cells as well as in the 
gene coding for the SAC-related factor (and BUBR1 
associated protein) AURKB (-2,62 and -3.31 fold decrease 
respectively). In order to approach the clinical relevance 
of these variations in BUBR1 levels as function of PTEN 
we used two available datasets: Oncomine and Array 
Express from EMBO-EBI. BUB1B gene expression was 
significantly increased in GBM patients (Figure 2C; p= 
2.2E-20, fold change 3.856, number of samples: normal 
brain n=23, glioblastoma n=81). Moreover, there was an 
inverse correlation between PTEN and BUB1B expression 
in GBM patients with low survival (Figure 2D; less than 
12 months; n=15, p<0.001, pearson -0.7592) further 
supporting that targeting BUBR1 (as PARPi does) could 
be used as rational therapy in PTEN deficient GBM. 
Interestingly, increased expression of BUB1B correlated 
with decreased patient survival (Figure 2E).
Another hallmark of genomic instability is 
micronuclei formation. Following PARP inhibition, 
U87MG cells, but not LN229 cells displayed a time-
Figure 1: Cell viability in PTEN wt LN229 and PTEN mut U87MG glioblastoma cell lines after treatment with PARP 
inhibitor (PJ34 20 μM if not detailed). A. Neurosphere Formation Assay (NFA) of GSCs TG1 treated with PJ34 or olaparib. The 
drug was refreshed the three first days of the experiment. After one week, neurosphere counting (10 fields of view per condition) was 
performed. *p < 0.05 versus control group by t-test. B.Viability analysis by MTT assay of glioblastoma cells treated with PJ34 for 24, 48 
and 72 hours. Data were normalized and expressed as a percentage of the control. *p < 0.05, **p < 0.01, ***p < 0.001 versus control group 
by t-test. C. Trypan blue intake counting was in order to check cell death. D. Apoptosis activation was determined 24, 48 and 72 hours after 
the treatment. SubG1 fraction was analysed by flow cytometry following staining with PI. **p < 0.01 versus control group by t-test. E. Cell 
cycle arrest was determined 24, 48 and 72 hours after the treatment. G2/M fraction was analysed by flow cytometry following staining with 
PI. **p < 0.01, ***p < 0.001 versus control group by t-test. F. Cell cycle profiles referring to control and PJ34 72 hours in both cell lines 
are represented. Data are represented as mean ± SEM of 3 independent experiments. 
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dependent accumulation of micronuclei (figure 2F). 
Polyploids are the result of cytokinesis failure after 
G2/M arrest. However PTEN-deficient cells, unable 
to activate the G2/M checkpoint, progress to continue 
cell cycle and complete aberrant mitosis. As shown in 
figure 1E, PARP inhibition-induced arrest in G2/M in 
PTEN-mutant cells was almost suppressed, implying that 
cells will progress in cell cycle, accumulating genomic 
instability, and eventually Mitotic Catastrophe but not 
polyploids (figure 2G, S4D). Interestingly, and consistent 
with increased G2/M arrest following PARPi after PTEN 
restoration (figure S2C), PTEN over-expression in 
U87MG also increased polyploidy (figure S2D). However, 
the slight increase observed after long-time of PJ34 
treatment suggests a possible interference of the genetic 
background of each cell line.
Taken together, these results led us to conclude that 
PARP inhibition compromised mitotic checkpoint through 
down-regulation of BUBR1, preventing from mitotic 
arrest only in a PTEN deficient context. 
To further understand the impact of PARP inhibition 
in PTEN mutant cells we performed an expression array 
focalized in genes involved in cell cycle regulation 
and DNA repair. In table 1 we have represented genes 
whose expression was significantly modified after 
PARP inhibition in U87MG cells. Up-regulated mRNAs 
included p53-dependent genes such as BBC3/PUMA (a 
pro-apoptotic bcl2 and BH3-only pro-apoptotic subclass) 
and CDKN1A/p21 (pro-apoptotic and CDK2 inhibitor). 
Up-regulation was also noted in genes involved in DNA 
damage, G2/M cell cycle checkpoint, and in genes 
implicated in DNA repair pathways such as XPA, XPC 
(Nucleotide Excision Repair). A number of down-regulated 
genes were involved in homologous recombination repair. 
That is the case for BARD1 and BRIP1, factors associated 
with BRCA1 who are needed for its activation. Moreover, 
RAD51 is an essential component of HR repair and its 
down-regulation could be detrimental for the cell to cope 
Figure 2: Mitotic instability following PARP inhibition (PJ34 20 μM). A. BUBR1 expression was measured by Western Blot 48 
hours after the treatment with PJ34. B. BUBR1 expression was measured by Western Blot after the treatment with PJ34 following PTEN 
silenting in LN229 cells/PTEN overexpression in U87MG cells. C. BUB1B gene expression analysis obtained with the Oncomine database; 
p= 2.2E-20, fold change 3.856; number of samples: normal brain n=23, glioblastoma n=81 D. BUB1B gene expression correlates negatively 
with PTEN expression in GBM low survival patients (less than 12 months); n=15, p<0.001, pearson -0.7592 E. BUB1B overexpression 
correlates with decreased patient survival. Data obtained from REMBRANDT database. n=413; 138 overexpressing BUB1B and 275 rest 
of samples. F. Micronuclei formation after DAPI staining was quantified. *p < 0.05, **p < 0.01 versus control group by t-test. G. Super G2 
fraction, indicating polyploid cells, was analysed by flow cytometry after staining with PI. *p < 0.05, **p < 0.01 versus control group by 
t-test. Data are represented as mean ± SEM of 3 independent experiments. 
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with DNA damage leading to cell death. Chk1, involved 
in cell cycle arrest after activation of ATM and ATR in 
response to DNA damage, is also down-regulated as 
well as the protein phosphatases CDC25A (which is a 
Chk1 substrate) and CDC25C, involved respectively in 
G1/S checkpoint and mitosis entry. Gene expression for 
exonuclease Exo1, that plays a role in mismatch repair, 
and the endonuclease FEN1, that removes 5’ overhanging 
flaps in DNA repair and processes the 5’ ends of Okazaki 
fragments in lagging strand DNA synthesis, is repressed 
after PARP inhibition. Mutations or deficiency in the 
Fanconi anemia complementation (FANC) group 
members is characterized by cytogenetic instability, 
hypersensitivity to DNA crosslinking agents, increased 
chromosomal breakage, and defective DNA repair. 
FANCG gene expression was also down-regulated after 
PARP inhibition. Phosphorylation of H2AX is involved 
in the initial early steps of DNA damage response, in the 
recognition of double strand breaks. Down-regulation of 
γH2AX is reflecting a strong defective signalling in the 
initial sensing of DNA lesions. Globally, this perturbation 
in DNA damage response factors after PARP inhibition 
suggests a discomposed scenario in the ability of these 
PTEN-deficient cells to cope with PARP inhibitor-induced 
DNA lesions that might be therapeutically exploited. 
Impaired Homologous Recombination (HR) after 
PARP inhibition in PTEN deficient glioma cells
In view of the above results we tested HR efficiency 
in U87MG and LN229 cell lines containing an integrated 
copy of the DR-GFP reporter as previously described [26]. 
This reporter allows to determine the rate of HR repair of 
a SceI endonuclease-generated DSB in the chromosome 
by the restoration of an intact green fluorescent protein 
(GFP) gene. GFP levels were quantified by Kolmogorov-
Smirnov adjust, and revealed that LN229 cells expressed 
higher levels of GFP after transfection, indicating that 
PTEN mutant cells are compromised in Homologous 
Recombination, as has been previously reported [20]. 
Moreover, PARP inhibition further disabled HR, mainly 
in PTEN mutant cells where we found this repair pathway 
profoundly down-regulated after the PARPi treatment 
(figure 3A).
To confirm the previous results of PARPi inducing 
increased HR deficiency specifically in PTEN mutant 
cells, we performed an assay to quantify RAD51 foci, 
which is also used to assess HR efficiency. First we 
observed that RAD51 accumulation in U87MG cells did 
not correlate with the level of DNA damage and did not 
fluctuate in parallel to γH2AX levels (figure S5A). On the 
contrary, RAD51 levels in LN229 raised in parallel with 
γH2AX levels and these foci were resolved following 
24 hours after irradiation. These results suggested that 
PTEN wild type cells, but not PTEN mutant cells, were 
able to couple HR activation with DNA damage levels. In 
addition, γH2AX basal levels are much lower in U87MG 
cells, further confirming the perturbed status of the HR 
signalling that makes them unable to properly signal and 
resolve DNA damage (figure S5B).
Consistently, assessing only cell bearing γH2AX 
foci, we observed that IR-induced accumulation of 
RAD51 foci was notably reduced in PTEN mutant cells 
(figure 3B) and co-treatment with PJ34 further decreased 
RAD51 foci formation in these cells, supporting the above 
results obtained with DR-GFP transfection assay. The 
levels of RAD51 were rapidly down-regulated in U87MG, 
but not in LN229 where they only decreased after 48 hours 
of PARP inhibition. PARP-1 silencing, however, affected 
similarly to RAD51 levels irrespective of the PTEN-status 
(figure 3C). Similar results were obtained using the PARPi 
olaparib (figure S4C). Levels of BRCA1 protein were also 
reduced in PTEN deficient cells (figure 3C). To further 
confirm the association between RAD51 decrease, PARPi 
treatment and PTEN status, we silenced PTEN in LN229 
and we found a decrease in RAD51 levels (figure 3D); 
on the other hand, restoring PTEN in U87MG cells led 
Table 1: Expression array of DNA repair proteins 
in U87MG glioblastoma cells. Genes over and under-
expressed following 24 hours PJ34 (20 μM) treatment. 
Data are represented as mean ± SEM of 3 independent 
experiments. P-value was calculated through t-test.
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to a delay in RAD51 down-regulation after the treatment 
(figure 3D).
As we described above, the expression of the 
SAC regulatory factor BUBR1 was reduced after PARPi 
treatment in PTEN mutant cells (figure 2A). To better 
understand the association between BUBR1 down-
regulation and impaired HR we knocked-down BUBR1 
in PTEN proficient cells and we observed a recovery in 
RAD51 following PARP inhibition (figure 3E). This 
apparently paradoxical result might be explained because 
PARP inhibition, in siBUBR1 cells, is acting in a BUBR1 
deficient scenario since the beginning, contrary to the 
situation on U87MG cells. RAD51 recovery might reflect 
a compensatory mechanism initiated by the cell to avoid 
massive DNA damage in the absence of an efficient 
mitotic checkpoint. 
PARP blockade potentiated in vitro and in vivo 
effect of EGFR inhibition on PTEN mutant 
glioma cells
In spite U87MG glioma cells are not mutant for 
EGFR, they constitutively activate MAP kinase pathway in 
virtue of mutations affecting Focal Adhesion Kinases and 
GRP3 [27, 28]. PARP inhibition did not prevent ERK1/2 
activation making this treatment only partially effective in 
suppressing this proliferative pathway. We reasoned that 
avoiding signalling arising from EGFR might deregulate 
the activation of MAP kinase pathway and potentiate the 
effect of PARP inhibition. While treatment with EGFR 
inhibitor erlotinib alone prevented ERK1/2 activation in 
LN229 cells, U87MG cells were refractory to the effect 
of erlotinib (figure 4A). Interestingly, co-treatment with 
PJ34 and erlotinib resulted in a complete suppression of 
Figure 3: Homologous Recombination (HR) is compromised following PARP inhibition. A. Stably transfected with DR-GFP 
plasmid LN229 and U87MG glioblastoma cell lines were transiently transfected with SceI plasmid. Two days later, they were treated with 
PARP inhibitor PJ34 (10 μM) for 48 hours. GFP expression was analysed by flow cytometry and the results were processed by Kolmogorov-
Smirnov test. **p < 0.01 by t-test. B. Distribution of Rad51 and γH2AX foci; nuclear staining was performed with DAPI. Cells were 
treated with PJ34 (20 μM) during 48 hours and subsequently irradiated at 2Gy during 4 hours. Fraction of positive γH2AX population 
bearing Rad51 foci was quantified. *p < 0.05, **p < 0.01, ***p < 0.001 versus control group by t-test. C. Homologous-Recombination 
(HR) proteins BRCA1 and Rad51 expression was analysed by western blot 24, 48 and 72 hours after 20 μM PJ34 treatment and following 
PARP knockdown. D. RAD51 expression was measured by Western Blot after the treatment with PJ34 following PTEN silenting in LN229 
cells/PTEN overexpression in U87MG cells. E.RAD51 expression was measured by Western Blot after the treatment with PJ34 following 
BUBR1 silenting in LN229 cells. Data are represented as mean ± SEM of 3 independent experiments. 
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ERK1/2 activation (figure 4B). Nonetheless, combination 
of both drugs did not further decrease the PARP inhibitor-
induced cytotoxicity (Figure 4C). 
The full abrogation of ERK1/2 activation prompted 
us to test the in vivo efficacy of this combination. To 
this end, we performed an orthotopic assay inoculating 
U87MG cells that expressed luciferase allowing in vivo 
visualisation of the evolution of tumour mass. While the 
effect of PJ34 or erlotinib were limited separately (35 and 
50% respectively), the combination of both treatments 
reduced tumour growth to more than 90% after 14 
days (figure 4D). Mice were sacrified after 21 days due 
excessive tumour growth in vehicle treated mice; at this 
time PJ34 continued to be effective as anti-tumour agent 
indicating that the combined inhibition of a pro-survival 
pathway (using erlotinib) together with the inactivation 
of HR and the induction of genomic instability by PARP 
inhibition has a synergic in vivo anti-tumour effect. 
DISCUSSION
Our reduced understanding of the mechanisms 
which underlie brain tumorigenesis severely limit 
preventative and therapeutic options for glioblastoma 
patients. The current standard treatment for GBM involves 
surgical resection followed by adjuvant radiotherapy (RT) 
with ionising radiation, with or without concomitant 
chemotherapy. Disappointingly, this regimen only 
affords GBM patients a median survival benefit of 14.6 
months- a 12 month improvement over resection alone. 
It is important to note that radio- and chemotherapies 
are, at the molecular level, based on inducing enough 
DNA damage in the tumour cell to result in lethality. The 
results shown in this study reflect that PARP inhibition 
results in a profound alteration of genomic instability in 
PTEN-deficient glioma cells affecting cell cycle, mitotic 
checkpoint and homologous recombination, leading to 
Figure 4: In vitro effect of EGFR inhibitor erlotinib and decreased tumours growth in vivo after combined treatment 
with PARP inhibitor and erlotinib. A. Western blot analysis of p-ERK-1/2 expression levels at different times following erlotinib 
treatment.. B,C. B,C. U87MG cells were treated with erlotinib alone or combined with PJ34 during 72 hours. (B) p-ERK-1/2 expression 
was measured by Western Blot. (C) MTT reduction was analysed. ***p < 0.001 versus control group by t-test. D. Mice were inoculated 
with U87MG-luciferase human cell line. Localization and intensity of luciferase expression were monitored by in vivo bioluminiscence 
imaging (dpi, days post cells injection). Representation of tumours growth inhibition on the 16th day. A statistically significant reduction is 
observed in the combined treatment of PJ34 and erlotinib. *p < 0.05 versus control group by t-test. Data are represented as mean ± SEM 
of 3 independent experiments. 
Oncotarget4797www.impactjournals.com/oncotarget
micronuclei formation, as hallmark of MC (Figure 5). The 
protein kinase BUBR1 plays a key role in the maintenance 
of chromosomal stability [29] owing to its involvement in 
the formation of proper chromosome-spindle attachments. 
First, BUBR1 down-regulation activates Aurora B kinase 
and the kinetochore protein CENP-A, resulting in the loss 
of kinetochore-microtubule attachments [30]. Second, 
BUBR1 avoids sister chromatids separation in anaphase 
when chromosome-spindle attachments are uncorrect, 
since it is involved on the Mitotic Checkpoint (Spindle 
Assembly Checkpoint or SAC) [31]. When interactions 
between kinetochores and microtubules are unstable 
in metaphase, BUBR1, acting together with MAD2 
and BUB3, join CDC20 avoiding APC activation thus 
preventing sister chromatids separation in anaphase. 
Remarkably gene expression of BUB1B (the gene coding 
for BUBR1) is very significantly up-regulated in GBM 
patients and its expression was inversely correlated with 
PTEN in short-survival patients. In line with this finding 
recently it has been described that BUB1B is differentially 
required for GSCs expansion in glioblastoma tumours and 
genetically transformed cells that have added requirement 
for BUB1B to suppress lethal consequences of altered 
kinetochore [32].
In the current study we have found that Homologous 
Recombination Repair deficiency in PTEN mutant glioma 
cells is further disabled after PARP inhibition due in part to 
RAD51 down-regulation. A previous study has shown that 
PARPi down-regulates RAD51 and BRCA1 leading to HR 
deficiency at times where an elevated loss of cell viability 
was observed [33]. In our study, PARP inhibition leads to a 
profound amplification of HR deficiency in PTEN mutant 
cells already at 24 hours (figure 3C and Table 1), where no 
cytotoxic effect is still appreciated (figure 1A). Moreover, 
the expression pattern of key components of the DNA 
damage response is strongly affected after blunting PARP 
activity, (PARP-1 of other PARP family members with 
poly (ADP-ribosyl)ation activity), including perturbation 
of the HR machinery and other DNA repair pathways 
as well as factors involved in genomic instability, 
beyond affecting RAD51. PTEN restoration in U87MG 
slowed RAD51 decrease, whereas PTEN silencing in 
LN229 augmented RAD51 down-regulation after PARP 
inhibition. Thus, we show that PTEN is involved in 
Figure 5: Different effect of PARPi in GBM according to PTEN status. First, in the absence of PTEN (left pannel) PARPi 
perturbs the correct segregation of chromosomes, due to BUBR1 down-regulation; secondly compromised integrity of the genomic material 
occurs as consequence of the alteration of HR repair. Both situations have been well-described to induce Mitotic Catastrophe. In contrast, 
in a PTEN-proficient context (right pannel) BUBR1 down-regulation is retarded allowing correct chromosome segregation in mitosis and, 
secondly, HR repair is less affected. Thus, mitotic and genomic instability are reduced and mitotic catastrophe-independent cell death 
pathways are activated.
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the mechanism by which PARP inhibition is disabling 
Homologous Recombination machinery, which should be 
taken into account in a possible clinical setting.
The benefit of combining PARP inhibitors with 
currently used chemotherapy has been largely reported 
including the potentiating effect of PJ34 [34, 35]. Here we 
also show compelling evidences that cell death pathway 
by which PARP inhibition impacts on cell viability of 
PTEN-deficient cells is MC. MC is a mechanism activated 
following genomic instability. It senses mitotic failure 
and responds to it by driving the cell to an irreversible 
fate, be it apoptosis, necrosis or senescence [36, 37]. The 
stimuli and perturbations that are described to trigger MC 
can be divided in two groups. The first group of inducers 
interfere with the faithful segregation of chromosomes in 
mitosis. The second group directly affects the integrity 
of the genetic material, for example DNA-damaging 
agents or compromised DNA-repair pathways. Thus, in 
our case, aberrant mitotic spindle organization and DNA 
segregation due to BUBR1 down-regulation constitute a 
“first-group inducer” of MC while impaired HR repair 
due to compromised RAD51 is “second trigger” of MC. 
However, in spite of the increasingly detailed description 
of the mechanisms that precede and follow MC, the 
molecular bridges between mitotic aberrations and cell 
death are still largely elusive. 
In an attempt to increase the in vivo cell killing 
effect of PARP inhibition on glioma cells we ideated 
(given the up-regulation of pro-survival signalling 
pathways in PTEN-deficient glioma cells) the co-treatment 
with an inhibitor of EGFR to disable pro-survival signals. 
Although no in vitro potentiation by erlotinib of PARP-
induced cytotoxic effect was observed, this combination 
was very effective in the suppression of ERK1/2 activation 
(figure 4B) and, more interestingly, in vivo co-treatment 
was synergic in slowing-down tumour growth. This 
enhanced in vivo potentiation using co-treatment of anti-
neoplastic agents with PARP inhibitors has been already 
described for different preclinical models and has been 
related to the increased vascular function after inhibition 
of PARP resulting in amelioration of drug availability in 
the tumour milieu [38]. Moreover, besides this general 
property of PARP inhibitors, the use of these compounds 
takes advantage of the elevated propensity to display 
genomic instability (which is related with aggressiveness 
trait) of PTEN deficient glioma cells. The ultimate 
mechanism underlying the synergistic effect of PARP1 and 
EGFR remains to be elucidated, but one possibility is that 
in specific settings inhibition of PARP with PJ34 activates 
pro-survival pathways as has been shown for p38/MAPK 
during osteoclast differentiation [39]. A different study has 
reported that PARP inhibitors may target different kinases 
in a cell-specific manner [40]. In addition to the shut-
down of EGFR signalling, other combinatorial treatments 
could be envisaged based on the rational knowledge of 
glioma cells molecular alterations. Another broad field 
to explore is the use of PARP inhibitors to act as radio-
potentiators against GBM and overcome tumour resistance 
to standard radiation therapy. In summary PARP inhibitors 
represent an exciting new class of antineoplasic drugs and 
there may well have much wider clinical indications not 
just restricted to BRCA1/2 mutant tumours but to others 
where PARP inhibitor treatment enhance HR deficiency 
and mitotic alterations, driving the cell towards a status of 
genomic instability.
MATERIALS AND METHODS
Cell Culture and Treatments
U87MG and U118MG PTEN mutant and LN229 
PTEN wild type (wt) glioblastoma cell lines as well as 
SW1783 PTEN mutant grade III astrocytoma cell line, 
were cultured in Dulbeco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % inactive fetal bovine 
serum (FBSi, Gibco Invitrogen), at 37 ºC in a humidified 
5% CO2 atmosphere. 
Patient-derived Glioma Stem Cell TG1 was obtained 
as described previously [41] and maintained in DMEM/
F12 plus N2, G5 and B27 (Invitrogen) at 37 ºC in a 
humidified 5% CO2 atmosphere. 
PARP inhibitors PJ34 (Alexis Biochemicals) and 
AZD2281/olaparib (Deltaclon) were used. Olaparib was 
dissolved in DMSO and PJ34 was dissolved in water. 
Both were stored at -20ºC. Cells were treated with 10 μM 
olaparib or 10 to 20 μM PJ34 during 24, 48 or 72 hours.
Temozolomide (T2577-25MG Sigma-Aldrich, St 
Louis, USA) was dissolved in DMSO and stored at -20ºC. 
Cells were treated with 100 μM Temozolomide during 24, 
48 or 72 hours. 
Viability Assays
Viability decrease was determined using MTT and 
Propidium Iodide. For MTT (3-(4, 5-Dimethylthiazol-2-
yl)-2,5-diphenyl Tetrazolium Bromide) assay, cells were 
plated in 96 wells at a density of 8 x 103 cells. MTT assay 
was performed using Cell Proliferation Kit I (MTT, 1-65-
007, Roche, Mh Germany) following manufacturer’s 
instructions. Global cell death assay was performed with 
Trypan Blue (Fluka analytical, 93595). Cells were plated 
in 24 wells at a density of 2 x 104 cells. One week after 
the treatment cells were trypsinized, washed with PBS 
and stained with Trypan Blue . Finally, cells were placed 
in a Neubauer counting chamber and counted in order to 




GSCs were dissociated by up-and-down pipetting 
and plated in 48 wells. PARP inhibitor was added every 
24 hours during the three first days of experiment [41]. 
GSCs were dissociated every day in order to check their 
ability to form seconday neurospheres at the end of the 
experiment. The 7th day, counts were blindly performed on 
10 fields of view, and the mean number of neurospheres 
per field of view was calculated.
Cell Cycle Assay
Cell cycle was analysed by flow cytometry [42]. 
Cells were plated in 6 wells at a density of 1.5 x 105 
cells. After the treatments, cells were trypsinized, washed 
with PBS, permeabilized with 70% ice cold ethanol, 
washed again with PBS and incubated with propidium 
iodide and 100 μg/ml RNAase A (Ribonuclease A from 
bovine pancreas R6513-10MG Sigma-Aldrich, St Louis, 
USA) for 20 min. When GFP population was examined, 
cell fixation before permeabilization was required, as 
previously described by Lamm et al [42]. Cells were 
analysed on a FACScan using CellQuest software, and 
cell cycle was determined using FlowJo software. In 
the case of PTEN overexpression, GFP population was 
gated in order to analyze cell cycle in a 100% transfected 
population.
Apoptosis Assays
Apoptosis was determined by different methods. 
a) Cell Cycle Assay: Sub G1 population was determined 
through Cell Cycle assay, as described above. b) Pyknotic 
nuclei: Cells were plated in 6 wells at a density of 5 x 
104 cells per well. 72 hours after the treatments cells 
were fixed in Paraformaldehyde (4%, wt/vol in PBS1x 
with 2% Sucrose) for 10 minutes at room temperature 
and incubated with DAPI for 10 minutes. The number of 
cells with nuclear apoptotic morphology was determined 
using a Zeiss Fluorescence Microscope. c) Caspase 3/7 
activity: Cells were plated in 96 wells at a density of 
6 x 103 cells per well. Following the treatments, The 
Caspase - Glo reagent (Promega) was added directly to 
cells and incubated at room temperature for 30 minutes 
before recording luminiscence in a TECAN infinite 200 
Luminometer. Each point represents the average of 3 wells 
per condition to 3 independent experiments. 
Western Blot Analysis
Cells were plated in 6 wells at a density of 2 x 105 
cells per well. After PARP inhibition, cells were washed 
twice with PBS and resuspended in 200 μl of TR3 
Lysis Buffer (3% SDS, 10% Glycerol, 10mM Na2HPO4 
anhidro). Then cells were sonicated and 20 μl of 50% 
β-mercaptoethanol - 50% Bromofenol blue were added. 
The protein concentration was determined using the Lowry 
assay. Proteins were resolved on SDS-polyacrylamide gels 
and transferred onto PVDF Membrane (Biorad). The blot 
was blocked with 5% milk powder in PBS1X with 0.1% 
Tween-20 for 60 minutes and incubated overnight with 
1% milk powder in PBS1X with 0.1% Tween-20 with 
the following antibodies: anti-PARP-1(C2-10 mouse, 
ALEXIS, LA), anti-PTEN (Santa Cruz Biotechnology sc-
7974), anti-BRCA1 (Santa Cruz Biotechnology sc-642), 
anti-RAD51 (Santa Cruz Biotechnology (H-92) sc-8349), 
anti-phosphoERK (Santa Cruz Biotechnology sc-7383), 
anti-ERK (Invitrogen. Carlsbad, CA 61-7400), anti-
phospho H2AX (Millipore 05-636) and anti-BUBR1 (BD 
Bioscience. Erembodegem, Belgium). α-Tubulin (Sigma, 
St Louis MO) and β-Actin (Sigma, St Louis MO) were 
used as loading control. Bands were visualized with ECL, 
ECL-PLUS and ECL PRIME (Amersham Biosciences) 
and the pictures were taken with the imaging system 
ChemiDoc XRS System (BIO-RAD) and medical X-ray 
films (AGFA). 
RNA interference
Cells were plated in 6 wells at a density of 9 x 104 
cells per well. 24 hours later, cells were transfected with 
the indicated siRNAs at 50 nM using Lipofectamine 
2000 transfection agent (Invitrogen) according to 
the manufacturer’s guide. Double-stranded RNA 
duplexes corresponding to a non-targeted control (5’–
CCUACAUCCCGAUCGAUGAUGUU-3’), PTEN 
(5´-GCUACCUGUUAAAGAAUCA-3´) and BUBR1 
(5´- CGGGCAUUUGAAUAUGAAA-3´) were ordered to 
SIGMA-ALDRICH, and double-stranded RNA duplexes 
corresponding to human PARP-1 were from Ambion 
Applied Biosystems. 48 hours after transfection, cells 
were treated with PARP inhibitors as indicated above.
PTEN restoration
Cells were plated in 6 wells at a density of 1 x 105 
cells per well. 24 hours later, transfection was performed 
with 0,5 μg pSG5L Flag HA Plasmid, pSG5L Myr HA 
PTEN Plasmid, GFP-PTEN Plasmid or pCDNA3-
GFP Plasmid (all from Addgene), using JetPRIME TM 
(Polyplus transfection, Illkirch, France) according to the 
manufacturer’s protocol. Cells were treated 48 hours after 
the transfection and harvested following the treatment in 
order to develop Cell Cycle and Western Blot analysis.
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Immunofluorescence
Cells were plated in 12 wells at a density of 2,5 x 
104 cells per well on glass cover-slips. After the treatments 
cells were fixed with Paraformaldehyde Solution (4%, wt/
vol in PBS1x with 2% Sucrose) for 10 minutes at room 
temperature and permeabilized with PBS 1X 0,5% Triton 
x100 for 5 minutes at room temperature. phospho-H2AX 
was detected by immunofluorescence, using monoclonal 
antibody (Millipore 05-636) at a dilution 1:250 and 
FITC-conjugated goat anti-mouse immunoglobulin 
(Sigma, St Louis Mo) at a dilution 1:400. RAD51 foci 
were detected using rabbit polyclonal IgG antibody (H-
92 Santa Cruz) 1:100 and FITC-conjugated goat anti-
rabbit 1:400. Nuclear counterstaining with DAPI was 
performed after removal of excess secondary antibody. 
Immunostaining was visualized with Confocal Leica LCS 
SP5 Fluorescence Microscope.
Homologous Recombination Assay
U87MG and LN229 glioma cells were stably 
transfected with a pDR-GFP plasmid containing a mutated 
GFP gene with an 18 bp SceI site and were maintained 
under puromycin selection before use. Transient 
transfection of SceI in both cell lines creates a DSB at 
the relevant site in the integrated GFP gene. Homologous 
recombination repair (HRR) of this break restores GFP 
gene expression [26]. 
Cells were plated in 6 wells at a density of 9 x 104 
cells per well for stable transfection with DR-GFP. 24 
hours later, cells were transfected with 1 μg DR-GFP 
plasmid per well using JetPEI TM (Polyplus transfection, 
Illkirch, France), according to the manufacturer’s protocol. 
Transfected cells were maintained under puromycin 
selection, and transfection was proved by PCR with the 
primers 
DRGFP1 5´AGGGCGGGGTTCGGCTTCTGG 3´
DRGFP2 5´CCTTCGGGCATGGCGGACTTGA 3´ 
For the transient transfection with SceI, cells were 
plated in 6 wells at a density of 9 x 104 cells per well. 24 
hours later, cells were transfected with 4 μg SceI plasmid 
per well using JetPRIMETM (Polyplus transfection, 
Illkirch, France) according to the manufacturer’s protocol. 
24 hours after the transfection, cells were treated with 
PJ34 hours during 48 hours. Finally, cells were trypsinized 
and percentage of GFP expressing cells was measured by 
flow cytometry on a FACScan.
Frequency of recombination events was calculated 
as mean percentage of GFP positive cells transfected with 
SceI divided by mean percentage of GFP positive cells 
transfected with pEGFP. Results were represented through 
Kolmogorov-Smirnov adjust using CellQuest software.
Additionally, homologous recombination was 
indirectly evaluated by the number of cells with rad51 
foci to get the fraction of γH2AX positive cells bearing 
Rad51 foci. Alt least 120 cells from three independent 
experiments were counted using Image J software. 
Micronucleus assay
DAPI counterstain described for pyknotic 
nuclei quantification was also used in order to analyse 
micronuclei frequency after PARP inhibition. Micronuclei 
counting was performed using Image J software.
DNA repair microarray
Cells were plated in p60 at a density of 1 x 
106 cells. RNA extraction was performed 24 hours 
after PJ34 treatment, with RNeasy MiniKit (Qiagen). 
Retrotranscription was developed with RT2 First Strand 
kit (Qiagen) and cDNA was tested by RT2 Profiler 
PCR Array - Human DNA Damage Signalling Pathway 
(Qiagen) according to the manufacturer´s protocol. Data 
were analysed by the ΔΔCt method. 
Ethics Statement
All human subjects data was publicly available in 
de-identified form on the Oncomine. website (https://
www.oncomine.org/) Therefore, its use was not classified 
as human subjects research, and no Institutional Review 
Board approval was needed.
Patient Datasets and Data Analysis
The microarray gene expression data was obtained 
from EMBO-EBI (http://www.ebi.ac.uk/arrayexpress/) 
and the clinical data was obtained from the database 
Oncomine (https://www.oncomine.org/) using data 
available on October 1st, 2010. Diagnoses were also 
made at the respective clinics. At the time of access, 343 
glioma patient samples with both gene expression data 
and corresponding survival times were available on the 
Rembrandt database. These included 413 GBMs, 138 
overexpressing BUB1B and 275 rest of samples.
In vivo bioluminescence assay
This study was performed in strict accordance 
with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the Bioethical Committee 
of CIBM-UGR. The protocol was approved by the 
Committee on the Ethics of Animal Experiments of the 
CIBM-UGR. All surgery was performed under ketamine 
– xylazine anesthesia, and every effort was made to 
minimize suffering.
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Thirteen-weeks-old male Balb/cnu/nu mice (Charles 
River Laboratories, Wilmington, MA, USA) were 
injected intracraneally with U87MG-luc cells (1x105) 
by introducing stereotactically the needle of a Hamilton 
syringe. The day after injection of tumour cells mice were 
treated three times per week mice with PJ34 at a dose 
of 10mg/kg body weight and/or erlotinib at a dose of 50 
mg/kg body weight injected intraperitoneally. Sodium 
Chloride solution/60% DMSO was used as vehicle. In 
order to develop in vivo bioluminiscence measurement, 
mice were injected intraperitoneally with D-luciferin 
solution dissolved in phosphate-buffered saline at a dose 
of 150 mg/kg body weight. After 5 minutes, the animals 
were anesthetized in the dark chamber using 3% isoflurane 
in air at 1.5 L/min and O2 at 0.2 L/min/mouse, and 
animals were imaged in a chamber connected to a camera 
(IVIS, Xenogen, Alameda, CA). The quantification of light 
emission was performed in photons/second/cm2/steradian 
using Living Image 2.6.1 software (Xenogen). Tumour 
growth was monitored at 0, 2, 8, 15 and 21 days by in 
vivo imaging and bioluminiscence measurement. After 
21 days, mice were sacrificed, and brains were dissected 
and placed in Petri dishes with D-luciferin solution at a 
dose of 20μg/ml. Ex vivo quantification of light emission 
was performed by introducing the petri dishes inside the 
chamber connected to IVIS as explained before. 
Statistical Analysis
Independent experiments were pooled when the 
coefficient of variance could be assumed identical. 
Statistical significance was evaluated using t-test 
(n=number of independent experiments). P-values below 
0.05 were considered significant.
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